These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
575 related articles for article (PubMed ID: 25096574)
1. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins. Renault TT; Elkholi R; Bharti A; Chipuk JE J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574 [TBL] [Abstract][Full Text] [Related]
2. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET. Liu Q; Leber B; Andrews DW Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112 [TBL] [Abstract][Full Text] [Related]
3. BH3 domains other than Bim and Bid can directly activate Bax/Bak. Du H; Wolf J; Schafer B; Moldoveanu T; Chipuk JE; Kuwana T J Biol Chem; 2011 Jan; 286(1):491-501. PubMed ID: 21041309 [TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714 [TBL] [Abstract][Full Text] [Related]
5. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Zhang J; Huang K; O'Neill KL; Pang X; Luo X Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874 [TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. Stauffer SR Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927 [TBL] [Abstract][Full Text] [Related]
7. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. Kodama T; Takehara T; Hikita H; Shimizu S; Shigekawa M; Li W; Miyagi T; Hosui A; Tatsumi T; Ishida H; Kanto T; Hiramatsu N; Yin XM; Hayashi N J Biol Chem; 2011 Apr; 286(16):13905-13. PubMed ID: 21367852 [TBL] [Abstract][Full Text] [Related]
8. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615 [TBL] [Abstract][Full Text] [Related]
9. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351 [TBL] [Abstract][Full Text] [Related]
10. BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hikita H; Takehara T; Kodama T; Shimizu S; Hosui A; Miyagi T; Tatsumi T; Ishida H; Ohkawa K; Li W; Kanto T; Hiramatsu N; Hennighausen L; Yin XM; Hayashi N Hepatology; 2009 Dec; 50(6):1972-80. PubMed ID: 19839062 [TBL] [Abstract][Full Text] [Related]
11. Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Shamas-Din A; Bindner S; Chi X; Leber B; Andrews DW; Fradin C Biochem J; 2015 May; 467(3):495-505. PubMed ID: 25714678 [TBL] [Abstract][Full Text] [Related]
12. Examining BCL-2 family function with large unilamellar vesicles. Asciolla JJ; Renault TT; Chipuk JE J Vis Exp; 2012 Oct; (68):. PubMed ID: 23070252 [TBL] [Abstract][Full Text] [Related]
13. Mimicking the BH3 domain to kill cancer cells. Ni Chonghaile T; Letai A Oncogene; 2008 Dec; 27 Suppl 1(0 1):S149-57. PubMed ID: 19641500 [TBL] [Abstract][Full Text] [Related]
14. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851 [TBL] [Abstract][Full Text] [Related]
15. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL. Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698 [TBL] [Abstract][Full Text] [Related]
16. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Certo M; Del Gaizo Moore V; Nishino M; Wei G; Korsmeyer S; Armstrong SA; Letai A Cancer Cell; 2006 May; 9(5):351-65. PubMed ID: 16697956 [TBL] [Abstract][Full Text] [Related]
17. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Del Gaizo Moore V; Schlis KD; Sallan SE; Armstrong SA; Letai A Blood; 2008 Feb; 111(4):2300-9. PubMed ID: 18056841 [TBL] [Abstract][Full Text] [Related]
19. Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions. Moroy G; Martin E; Dejaegere A; Stote RH J Biol Chem; 2009 Jun; 284(26):17499-511. PubMed ID: 19293158 [TBL] [Abstract][Full Text] [Related]
20. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. Buron N; Porceddu M; Brabant M; Desgué D; Racoeur C; Lassalle M; Péchoux C; Rustin P; Jacotot E; Borgne-Sanchez A PLoS One; 2010 Mar; 5(3):e9924. PubMed ID: 20360986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]